These preclinical studies outline a CRISPR-based methodology for correcting β-globin gene mutations in haematopoietic stem cells to advance the development of next-generation therapies for β-haemoglobinopathies.
- Daniel P. Dever
- Rasmus O. Bak
- Matthew H. Porteus